

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Prescient Therapeutics Limited
ABN	56 006 569 106

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Steven Lee Yatomi-Clarke
Date of last notice	17 December 2020

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Arrow Wealth Ltd <Berbay Family A/C> (a controlled entity of Mr Yatomi-Clarke) Novetera Pty Ltd <SAYC Super Fund A/C> (a controlled entity of Mr Yatomi-Clarke) Alexandra Elizabeth Yatomi-Clarke
Date of change	11 October 2022

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

<p>No. of securities held prior to change</p>	<p>Direct 4,000,000 Fully paid ordinary shares</p> <p>2,000,000 Unlisted Options exercisable at \$0.1016 (10.16 cents) per option, expiring 18 December 2022</p> <p>3,500,000 Unlisted Options, exercisable at \$0.0663 (6.63 cents) per option, expiring on 2 May 2023</p> <p>Indirect <u>Arrow Wealth Ltd</u> 3,245,000 Fully paid ordinary shares <u>Novetera Pty Ltd</u> 1,717,750 Fully paid ordinary shares 97,692 Listed PTXOC Options, exercisable at \$0.0625 (6.25 cents) per option, expiring on 31 March 2023 12,900,000 Unlisted Options, exercisable at \$0.0968 (9.68 cents) per option, expiring on 23 November 2024 <u>Alexandra Elizabeth Yatomi-Clarke</u> 172,500 Fully paid ordinary shares</p>
<p>Class</p>	<p>Fully Paid Ordinary Shares</p>
<p>Number acquired</p>	<p>171,428</p>
<p>Number disposed</p>	<p>-</p>
<p>Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation</p>	<p>\$30,000.00</p>
<p>No. of securities held after change</p>	<p>Direct 4,000,000 Fully paid ordinary shares</p> <p>2,000,000 Unlisted Options exercisable at \$0.1016 (10.16 cents) per option, expiring 18 December 2022</p> <p>3,500,000 Unlisted Options, exercisable at \$0.0663 (6.63 cents) per option, expiring on 2 May 2023</p> <p>Indirect <u>Arrow Wealth Ltd</u> 3,245,000 Fully paid ordinary shares <u>Novetera Pty Ltd</u> 1,889,178 Fully paid ordinary shares 97,692 Listed PTXOC Options, exercisable at \$0.0625 (6.25 cents) per option, expiring on 31 March 2023 12,900,000 Unlisted Options, exercisable at \$0.0968 (9.68 cents) per option, expiring on 23 November 2024 <u>Alexandra Elizabeth Yatomi-Clarke</u> 172,500 Fully paid ordinary shares</p>

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issued pursuant to Share Purchase Plan announced on 24 August 2022.
---	---

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Prescient Therapeutics Limited
ABN	56 006 569 106

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	James Campbell
Date of last notice	17 December 2020

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Fusion Biosciences Pty Ltd (Director and Beneficiary)
Date of change	11 October 2022
No. of securities held prior to change	<p>Direct</p> <p>213,750 Fully Paid Ordinary Shares</p> <p>17,813 Listed PTXOC Options, exercisable at \$0.0625 (6.25 cents) per option, expiring on 31 March 2023</p> <p>415,000 Unlisted Options, exercisable at \$0.0633 (6.63 cents) per option, expiring on 2 May 2023</p> <p>Indirect</p> <p><i>Fusion Biosciences Pty Ltd</i></p> <p>1,000,000 Unlisted Options, exercisable at \$0.0968 (9.68 cents) per option, expiring on 23 November 2024</p>
Class	Fully Paid Ordinary Shares
Number acquired	28,571

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

Number disposed	-
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$5,000.00
No. of securities held after change	<p>Direct</p> <p>242,321 Fully Paid Ordinary Shares</p> <p>17,813 Listed PTXOC Options, exercisable at \$0.0625 (6.25 cents) per option, expiring on 31 March 2023</p> <p>415,000 Unlisted Options, exercisable at \$0.0633 (6.63 cents) per option, expiring on 2 May 2023</p> <p>Indirect</p> <p><i>Fusion Biosciences Pty Ltd</i></p> <p>1,000,000 Unlisted Options, exercisable at \$0.0968 (9.68 cents) per option, expiring on 23 November 2024</p>
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issued pursuant to Share Purchase Plan announced on 24 August 2022.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
--	----

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.